Abdominal MR Imaging with a Volumetric Interpolated Breath-hold Examination1
Rofsky N, Lee V, Laub G, Pollack M, Krinsky G, Thomasson D, Ambrosino M, Weinreb J. Abdominal MR Imaging with a Volumetric Interpolated Breath-hold Examination1. Radiology 1999, 212: 876-84. PMID: 10478260, DOI: 10.1148/radiology.212.3.r99se34876.Peer-Reviewed Original ResearchA multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis
Small W, DeSimone‐Macchi D, Parker J, Sukerkar A, Hahn P, Rubin D, Zelch J, Kuhlman J, Outwater E, Weinreb J, Brown J, de Lange E, Woodward P, Arildsen R, Foster G, Runge V, Aisen A, Muroff L, Thoeni R, Parisky Y, Tanenbaum L, Totterman S, Herfkens R, Knudsen J, Laster R, Duerinckx A, Stillman A, Spritzer C, Saini S, Rofsky N, Bernardino M. A multisite phase III study of the safety and efficacy of a new manganese chloride‐based gastrointestinal contrast agent for MRI of the abdomen and pelvis. Journal Of Magnetic Resonance Imaging 1999, 10: 15-24. PMID: 10398973, DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsGastrointestinal contrast agentAdverse eventsSite investigatorsGastrointestinal tract side effectsPatient diagnosisBlinded readersMore adverse eventsPhase III studyInflammatory bowel diseaseGroup of patientsPeptic ulcer diseaseML of placeboT2-weighted MRI scansMultisite clinical trialContrast agentsOral contrast agentAdditional diagnostic informationPlacebo patientsOral agentsIII studyBowel diseaseUlcer diseaseGastrointestinal pathologyLaboratory changesPhysical examination